** Shares of drug developer Q32 Bio fall 67.64% to $7.90 after market

** QTTB says its experimental drug bempikibart failed to meet the main goal in a part of a mid-stage trial studying it in patients with atopic dermatitis

** The two-part trial was evaluating the drug in adults with atopic dermatitis, a condition that causes dry, itchy and inflamed skin

** Co plans to conduct a review to better understand the results

** In another trial, bempikibart showed improvement in patients with alopecia areata, an autoimmune disease that causes hair loss in patches

** Based on the results, QTTB plans to advance development of bempikibart in patients with the hair condition

** Up to last close, stock up ~123% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com))